We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche's Infectious Disease Portfolio To Include HCV Immunodiagnostics

By HospiMedica staff writers
Posted on 26 Nov 2007
Hepatitis C virus (HCV) infections frequently result in chronic liver disease. More...
They represent a major cause of death through the development of liver cirrhosis and liver cancer. HCV antibody tests are used for the primary diagnosis of HCV virus infection in patients with suspected liver disease. Positive anti-HCV results indicate the need for further investigation such as nucleic acid testing for viral RNA. Prognosis of HCV infection can be improved by anti-viral treatment, specifically interferon, and can be monitored using diagnostic tests.

Roche (Basel, Switzerland) announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. (Raritan, NJ, USA) and Novartis Vaccines & Diagnostics (Frimley/Camberley, UK) in the field of HCV diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for HCV in the field of immunodiagnostics. The agreement also includes cross licensing of patents owned by Roche Diagnostics. Financial terms of the deal were not disclosed.

The licensing agreement for HCV immunoassays will enable Roche Professional Diagnostics to expand its comprehensive product range in infectious diseases and to become a major player in this field, having already achieved a leading position in nucleic acid testing for hepatitis and retroviruses.

"We are pleased to have reached an agreement that provides Roche Diagnostics worldwide access to HCV immunoassays. This agreement will strengthen Roche's position in infectious disease diagnostics and will drive further growth of our immunoassay business worldwide,” commented Dirk Ehlers, head of Roche Professional Diagnostics.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology, and active in other therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders, and diseases of the central nervous system (CNS).


Related Links:
Roche
Ortho-Clinical Diagnostics
Novartis Vaccines & Diagnostics

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Immunofluorescence Analyzer
IFA System
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.